How worried should we be about blood clots linked to AstraZeneca, J&J vaccines?
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard
THURSDAY, MAY 26, 2022
THURSDAY, MAY 26, 2022
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
How worried should we be about blood clots linked to AstraZeneca, J&J vaccines?

Coronavirus chronicle

Reuters
27 May, 2021, 07:40 pm
Last modified: 27 May, 2021, 07:47 pm

Related News

  • Pfizer says 3 Covid shots protect children under 5
  • Covax calls for urgent action to close vaccine equity gap
  • Main negotiators reach 'outcome' on Covid vaccine IP waiver, WTO says
  • Britain approves Valneva's easy-to-store Covid shot
  • 95% of target population fully vaccinated: Health Minister

How worried should we be about blood clots linked to AstraZeneca, J&J vaccines?

Amid concerns that reports of rare side-effects could undermine vaccine confidence, experts have emphasised that clotting risks for both shots remain extremely low and the vaccines are highly effective in preventing Covid-19 deaths and severe disease

Reuters
27 May, 2021, 07:40 pm
Last modified: 27 May, 2021, 07:47 pm
AstraZeneca logo is reflected in a drop on a syringe needle in this illustration photo taken March 16, 2021. Picture taken March 16, 2021. REUTERS/Dado Ruvic/Illustration/File Photo
AstraZeneca logo is reflected in a drop on a syringe needle in this illustration photo taken March 16, 2021. Picture taken March 16, 2021. REUTERS/Dado Ruvic/Illustration/File Photo

International drug regulators have said the benefits of using Covid-19 vaccines developed by Johnson & Johnson and AstraZeneca outweigh risks as they investigate reports of extremely rare, but potentially fatal blood clots.

Several EU countries have restricted their use.

Amid concerns that reports of rare side-effects could undermine vaccine confidence, experts have emphasised that clotting risks for both shots remain extremely low and the vaccines are highly effective in preventing Covid-19 deaths and severe disease.

Here's what we know so far:

What has happened?

With both the AstraZeneca and J&J vaccines, the reports involve extremely rare clotting, mainly a type of blood clot called cerebral venous sinus thrombosis (CVST), seen in combination with low blood platelet levels, called thrombocytopenia.

The European Medicines Agency (EMA) said most clots had occurred in the brain and abdomen.

The US Centers for Disease Control (CDC) said the clotting events have been documented in numerous areas of the body, including the femoral vein and artery, internal jugular vein, upper extremity veins and the pulmonary artery.

As of April 20, there had been more than 300 clotting incidents with low platelets reported, out of tens of millions of shots administered.

That included 287 cases of clotting - including CVST and splanchnic vein thrombosis (SVT) which is clotting in veins in the abdomen - linked to the AstraZeneca vaccine.

Europe's regulator is now reviewing the first report in the region of a death potentially linked to J&J's vaccine, after a 37-year-old woman in Belgium suffered from a blood clot with low platelets.

More than 1.34 million J&J doses have been administered within the EU.

What have the companies said?

J&J has said that no clear causal relationship has been established between the vaccine and the clots.

It resumed shipping its one-dose vaccine to Europe and the United States in late April with a warning on its label after a brief pause due to US clotting cases.

AstraZeneca, whose vaccine packaging also includes a warning label required by regulators, has said it is working to understand individual cases and "possible mechanisms that could explain these extremely rare events".

What have regulators said?

The CDC has said it has found a "plausible causal association" between J&J's shot and clotting after identifying 28 cases of the side-effects among around 9 million people who had received J&J's vaccine.

The US Food and Drug Administration has said the vaccine is safe and effective in preventing Covid-19, while issuing guidance to medical professionals on how to respond, should clots emerge.

Europe's drug regulator has also found a possible link between rare clotting and J&J and AstraZeneca shots, but maintained the benefits of getting vaccinated outweighed the risks.

It has recommended that anyone who developed blood clots with low blood platelets after receiving the first dose should get an alternative shot for the second dose.

The agency has left it up to individual countries to decide how to administer the shots, saying factors may vary including infection rates and whether there are vaccine alternatives to influence local policies.

Britain's Medicines and Healthcare products Regulatory Agency recommended people under 40 get an alternative vaccine to AstraZeneca's citing low levels of Covid-19 infection there and the availability of other vaccines.

Any theories on cause of the clots?

Among possible causes being investigated is that the vaccine triggers an unusual antibody response in rare cases. So far, risk factors like age or gender have not been singled out.

Health regulators and scientists are exploring whether the clotting problem may affect the whole class of so-called viral vector vaccines, which the EMA said was possible, while noting differences in the two shots, including the vectors they use to deliver vaccine material.

A group of German researchers said their laboratory research showed the rare clotting events were linked to the cold viruses used to deliver vaccine material to the body.

Separate teams of German scientists at Greifswald University and Norwegian scientists have concluded the extremely rare cases of clotting with low platelets are triggered in part by antibodies found in the affected patients who received AstraZeneca's shot.

Explainer / Top News

covid-19 vaccine / blood clot

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Photo: Bloomberg
    Bigger food crisis can be averted if Asia remembers not to panic
  • One exchange rate for all to ease dollar volatility
    One exchange rate for all to ease dollar volatility
  • Tax amnesty, relaxed remittance rules to bring back laundered money: Kamal
    Tax amnesty, relaxed remittance rules to bring back laundered money: Kamal

MOST VIEWED

  • People in protective suits cross a street during lockdown, amid the coronavirus disease (COVID-19) pandemic, in Shanghai, China, May 26, 2022. REUTERS/Aly Song
    Shanghai heading out of lockdown but China still lost in economic gloom
  • A woman wearing a face mask crosses a road at the Central Business District (CBD), amid the coronavirus disease (Covid-19) outbreak in Beijing, China May 10, 2022. REUTERS/Carlos Garcia Rawlins
    Tightening Covid net, Beijing deals out punishments, stark warnings
  • A medical worker takes a swab sample from a person for a nucleic acid test at a makeshift testing site, amid the coronavirus disease (Covid-19) outbreak, in Beijing, China May 23, 2022. REUTERS/Tingshu Wang
    Beijing ramps up Covid quarantine, Shanghai residents decry uneven rules
  • A vial labelled with the Pfizer-BioNTech coronavirus disease (Covid-19) vaccine is seen in this illustration picture taken March 19, 2021. Photo :Reuters
    Pfizer says 3 Covid shots protect children under 5
  • A medical worker takes a swab sample from a person for a nucleic acid test at a makeshift testing site, amid the coronavirus disease (Covid-19) outbreak, in Beijing, China May 23, 2022. REUTERS/Tingshu Wang
    Beijing urges millions to keep working from home amid Covid outbreak menace
  • Picture: PTI
    Saudi Arabia bans travel to India, 15 other countries over Covid outbreaks

Related News

  • Pfizer says 3 Covid shots protect children under 5
  • Covax calls for urgent action to close vaccine equity gap
  • Main negotiators reach 'outcome' on Covid vaccine IP waiver, WTO says
  • Britain approves Valneva's easy-to-store Covid shot
  • 95% of target population fully vaccinated: Health Minister

Features

Photo caption: Business models are already being hit by climate risk. It is the function of regulators to force banks to pay attention to the future risks to businesses. Photo: Bloomberg

HSBC and its discordant climate songbook

6h | Panorama
Illustration: TBS

Should Belayets be allowed to return to school at 55?

10h | Pursuit
Impact Hub Dhaka is designed to cater to connectivity, offering lots of communal areas where you can chat over coffee, watch a webinar as a group or even host events. Photo: Courtesy

Inside Impact Hub: The surprising benefits of working in a co-working space

11h | Pursuit
Pacific Jeans uses sustainable technology in washing and finishing, and now has the facility to wash with zero water. Photo: Courtesy

How big dreams and smart investment made Pacific Jeans a denim exporting giant 

12h | Panorama

More Videos from TBS

5 latest exciting movies

5 latest exciting movies

4h | Videos
Why is Thanda Garam's juice so popular?

Why is Thanda Garam's juice so popular?

10h | Videos
Tea tales at TSC

Tea tales at TSC

11h | Videos
What journalism students want to know

What journalism students want to know

12h | Videos

Most Read

1
Tk100 for bike, Tk2,400 for bus to cross Padma Bridge
Bangladesh

Tk100 for bike, Tk2,400 for bus to cross Padma Bridge

2
Bangladesh at risk of losing ownership of Banglar Samriddhi
Bangladesh

Bangladesh at risk of losing ownership of Banglar Samriddhi

3
BSEC launches probe against Abul Khayer Hero and allies
Stocks

BSEC launches probe against Abul Khayer Hero and allies

4
Photo: Courtesy
Panorama

Misfit Technologies: A Singaporean startup rooted firmly in Bangladesh

5
Illustration: TBS
Banking

Let taka slide

6
Photo: Collected
Industry

Spanish recycled cotton producer opens new facility in Bangladesh

The Business Standard
Top
  • Home
  • Entertainment
  • Sports
  • About Us
  • Bangladesh
  • International
  • Privacy Policy
  • Comment Policy
  • Contact Us
  • Economy
  • Sitemap
  • RSS

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net

Copyright © 2022 THE BUSINESS STANDARD All rights reserved. Technical Partner: RSI Lab